Fabry nephropathy: a review - how can we optimize the management of Fabry nephropathy?

BMC Nephrol · 2014 · PMC4029839 · PMID 24886109

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

A recent short-term study assessing three doses of agalsidase alfa (0.2 mg every 2 weeks; 0.1 mg and 0.2 mg every week) showed a trend for the higher dose to be most effective suggesting a longer-term study was needed [ 76 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.